FDA Authorizes First Wearable That Continuously Tracks Both Glucose and Ketones

The U.S. Food and Drug Administration has authorized what it describes as the first wearable device capable of continuously monitoring both ketone levels and blood sugar in a single sensor, according to an FDA press release. The device, called the Libre Duo 10 Day Continuous Dual Glucose Ketone Monitoring System, is authorized for people aged 2 years and older who are living with diabetes, as the FDA stated in its announcement.

This is a notable step in the evolution of continuous glucose monitoring (CGM), a category that has largely been defined by single-analyte sensors tracking glucose alone. The FDA's authorization of a combined glucose-and-ketone sensor signals a shift toward wearables that can flag more than one physiological signal at a time, without requiring a separate fingerstick test or standalone meter for ketones.

Why pairing glucose and ketones matters

For people managing diabetes, glucose and ketones are related but distinct signals. Elevated ketones alongside high blood sugar can be an early warning sign of diabetic ketoacidosis (DKA), a serious complication that develops when the body starts breaking down fat for fuel due to insufficient insulin. Historically, checking ketone levels has required a separate blood or urine test, meaning the information often arrived later and with more friction than a continuous glucose reading.

By combining both measurements into a single continuously worn sensor, a device like the Libre Duo 10 Day system, as authorized by the FDA, could in principle make it easier for someone to notice a combined rise in glucose and ketones sooner. The FDA's release does not specify performance data, accuracy figures, or clinical study results, so it is worth being precise about what has actually been confirmed: the agency has authorized the device for marketing, and it is intended for continuous dual monitoring in people aged 2 and older with diabetes.

What the FDA release does — and doesn't — say

• The device is named the Libre Duo 10 Day Continuous Dual Glucose Ketone Monitoring System, per the FDA announcement.
• It is authorized for people aged 2 years and older living with diabetes, according to the FDA.
• The FDA describes it as the first wearable authorized to continuously monitor both ketone levels and blood sugar.

The source material does not include details on sensor wear duration beyond the "10 Day" naming convention, accuracy benchmarks, pricing, insurance coverage, or a launch timeline for availability. Those specifics were not part of the FDA's announcement as excerpted, so we are not speculating on them here.

Where this fits in the broader wearable landscape

Consumer wearables like smartwatches and rings have increasingly branched into metabolic health territory — some track skin temperature, heart rate variability, and sleep patterns that are loosely associated with metabolic and recovery states. But glucose and ketone monitoring remain squarely in medical-device territory, requiring FDA authorization and, in most cases, a prescription or clinical oversight, because the readings can directly inform insulin dosing and emergency decision-making.

A dual-analyte continuous monitor sits at the intersection of two trends that BioDataHQ has tracked closely: the push toward fewer, more integrated biosensors, and growing interest in real-time metabolic feedback outside of a clinical setting. For people with type 1 diabetes in particular, who face the highest DKA risk, having glucose and ketone trends on the same continuous feed — rather than needing a separate ketone check — may reduce the lag between a metabolic warning sign appearing and it being noticed.

What to watch next

Because the FDA's announcement is the only information available at this stage, several open questions remain unanswered publicly:

• How the device's ketone-sensing accuracy compares to existing blood or urine ketone tests.
• Whether it will integrate with existing insulin pump or automated insulin delivery ecosystems.
• Retail availability, cost, and insurance coverage in the U.S. market.
• Whether companion consumer wearables (smartwatches, rings) will eventually offer any complementary display or alerting for this kind of data, as has happened with existing single-analyte CGMs.

For now, the headline development is regulatory rather than consumer-facing: the FDA has authorized the first wearable that continuously tracks both glucose and ketones together, expanding what a single diabetes-monitoring sensor can do. As with any new monitoring technology, people with diabetes should discuss whether and how a device like this fits into their care plan with their healthcare provider rather than treating it as a replacement for medical guidance.

BioDataHQ will continue tracking how this authorization translates into actual product availability, and whether other manufacturers follow with their own dual-analyte continuous monitors.